TITLE:
Changes in Antiretroviral Regimens among People Living with HIV Followed at the Diocesan Center of N’Djamena, Chad
AUTHORS:
Abdoulaye Anou Nassour, Adoum Fouda Abderrazzack, Masna Raksala, Tchonfiene Passiri Patedjoré, Emmanuel Issa, Oumalkher Youssouf Adam, Alain Nahaskida, Fridam Dounia, Adawaye Chatte, Demal Chantal, Dillah Christian, Ahmat Mahamat Ahmat, Serge Mbaitoloum Beoudal, Souleymane Habib Ahmat, Brahim Boy Otchom, Ali Mahamat Moussa, Abdelsalam Tidjani, Ameyapoh Yaovi, Franck Jean Daniel Mennechet
KEYWORDS:
Treatment Switch, Antiretrovirals, HIV, Dolutegravir, Chad, CEDIAM
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.15 No.3,
August
21,
2025
ABSTRACT: Introduction: Switching antiretroviral (ARV) regimens is a key component in optimizing the long-term management of people living with HIV (PLWH). This study aims to analyze the profiles and reasons for antiretroviral therapy (ART) changes among patients followed at the Diocesan Center for Information and Support of Patients (CEDIAM) in N’Djamena between January 2022 and August 2024. Methods: A prospective cross-sectional study was conducted among adult patients receiving ART. Data were collected using a standardized form through patient interviews and review of medical records, and analyzed using Epi Info 3.5.2 software. Results: Of the 573 patients on ART, 253 were included, representing a participation rate of 44.15%. Nearly all patients (99.2%) were infected with HIV-1. At initiation, 65.21% were on a TDF/FTC/EFV-based regimen. The majority of regimen changes (90.51%) involved a transition to Dolutegravir-based regimens. Additionally, 61.7% of patients experienced a single treatment change, while 6.7% had three changes. Conclusion: Changes in ARV regimens should be based on national treatment guidelines and accompanied by rigorous follow-up. Therapeutic adherence remains a key factor in virological success, emphasizing the importance of continuous patient education throughout the care pathway.